Common Terminology Criteria for Adverse Events
Names
More detailed information about this field from each metasource.
Common Terminology Criteria for Adverse Events
metasource: Fairsharing.org
version: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
metasource: Biontology / Bioportal
version: 5.0 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/CTCAE
CTCAE
metasource: Fairsharing.org
version: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
metasource: Biontology / Bioportal
version: 5.0 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/CTCAE
Names
More detailed information about this field from each metasource.
Common Terminology Criteria for Adverse Events
metasource: Fairsharing.orgversion: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
metasource: Biontology / Bioportal
version: 5.0 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/CTCAE
CTCAE
metasource: Fairsharing.orgversion: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
metasource: Biontology / Bioportal
version: 5.0 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/CTCAE
Names
More detailed information about this field from each metasource.
Common Terminology Criteria for Adverse Events
metasource: Fairsharing.orgversion: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
metasource: Biontology / Bioportal
version: 5.0 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/CTCAE
CTCAE
metasource: Fairsharing.orgversion: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
metasource: Biontology / Bioportal
version: 5.0 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/CTCAE
A coding system for reporting adverse events that occur in the course of cancer therapy. It was derived from the Common Toxicity Criteria (CTC) v2.0 and is maintained by the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institution (NCI).
Description
More detailed information about this field from each metasource.
A coding system for reporting adverse events that occur in the course of cancer therapy. It was derived from the Common Toxicity Criteria (CTC) v2.0 and is maintained by the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institution (NCI).
metasource: Fairsharing.orgversion: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
Common Terminology Criteria for Adverse Events (CTCAE) is widely accepted throughout the oncology community as the standard classification and severity grading scale for adverse events in cancer therapy clinical trials and other oncology settings. Version 5 was published by the NCI Cancer Therapy Evaluation Program (CTEP) in November 2017. It is organized by MedDRA System Organ Class and mapped to MedDRA LLTs with corresponding MedDRA codes, and harmonized with MedDRA at the Adverse Event (AE) level including revised AE terms and severity indicators to reflect clinical effects identified with current oncology interventions.Severity grades are assigned and most are defined to clarify the meaning of the term. CTCAE is designed to integrate into information networks for safety data exchange, and is the primary standard for data management for AE data collection, analysis, and patient outcomes associated with cancer research and care.
metasource: Biontology / Bioportalversion: 5.0 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/CTCAE
Webpage:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmWebpage
More detailed information about this field from each metasource.
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
metasource: Fairsharing.orgversion: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
https://nciterms.nci.nih.gov/ncitbrowser/pages/vocabulary.jsf?dictionary=CTCAE_v5&version=5.0
metasource: Biontology / Bioportalversion: 5.0 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/CTCAE
Publications:
Publications
More detailed information about this field from each metasource.
Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0
PMID: 19379294
metasource: Fairsharing.org
version: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
Publications
More detailed information about this field from each metasource.
Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0
PMID: 19379294
metasource: Fairsharing.org
version: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
-
Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0
PubMed citations: 75.
75 articles citing: Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0
Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib). PMID:33764261
Evaluating the use of cytosine arabinoside for treatment for recurrent canine steroid-responsive meningitis-arteritis. PMID:33638531
Treatment of genitourinary carcinoma in dogs using nonsteroidal anti-inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study. PMID:33634516
Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients? PMID:33604459
Cutaneous wound healing: canine allogeneic ASC therapy. PMID:32600465
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. PMID:32443457
Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma. PMID:32187827
Comparison of the efficacy of cyclosporine and leflunomide in treating inflammatory colorectal polyps in miniature dachshunds. PMID:32062634
Multidose intramuscular allogeneic adipose stem cells decrease the severity of canine atopic dermatitis: A pilot study. PMID:32025111
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs. PMID:31977135
Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors. PMID:31814640
Metastatic Cardiac Hemangiosarcoma in a 6 Year Old Wheaten Terrier Mix. PMID:31340545
Development of an oligonucleotide microarray for simultaneous detection of two canine MDR1 genotypes and association between genotypes and chemotherapy side effects. PMID:30481983
In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PMID:30192852
Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour. PMID:30117719
Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma. PMID:30081470
Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma. PMID:30060548
Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors. PMID:29387214
c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. PMID:29194765
Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats. PMID:29146945
A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma. PMID:29067193
Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. PMID:28969639
The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma. PMID:28725110
Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, intravenous, and intraperitoneal administration of cyclophosphamide. PMID:28650232
Marked cytoreduction of a lymphocyte-rich mediastinal thymoma with neoadjuvant chemotherapy in a cat. PMID:28491357
Ovarian carcinomatosis in a dog managed with surgery and intraperitoneal, systemic, and intrapleural chemotherapy utilizing indwelling pleural access ports. PMID:28487593
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR. PMID:28193671
Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer. PMID:28042155
Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats. PMID:27805594
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PMID:27434128
Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles. PMID:27119092
Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model. PMID:27050167
Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. PMID:26933263
Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012. PMID:26834270
Subcutaneous administration of paclitaxel in dogs with cancer: A preliminary study. PMID:26246628
Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs. PMID:26119008
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. PMID:26062540
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PMID:25923466
An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors. PMID:25818216
Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma. PMID:25762364
Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. PMID:25619518
Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. PMID:25274443
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. PMID:25122639
Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. PMID:24991836
Phase I dose-escalation study of nimustine in tumor-bearing dogs. PMID:24521794
The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma. PMID:24489398
GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma. PMID:24460928
Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan. PMID:24441652
Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma. PMID:24422857
Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial. PMID:24118677
A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes. PMID:24082004
Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012). PMID:23721492
Chemotherapy and radiation therapy in 4 dogs with muscle-invasive transitional cell carcinoma of the urinary tract. PMID:23372196
Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. PMID:23176425
Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma. PMID:22540967
A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. PMID:22390318
Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study. PMID:22235914
Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. PMID:22204296
Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. PMID:22099988
Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma. PMID:22077408
Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PMID:22073242
Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs. PMID:22072863
Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma. PMID:21564295
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. PMID:21509468
Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma. PMID:21488959
The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: a pilot study. PMID:21461200
Treatment of feline gastrointestinal small-cell lymphoma with chlorambucil and glucocorticoids. PMID:21041334
Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound. PMID:20823163
Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. PMID:20705615
Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study. PMID:20691026
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. PMID:20615965
Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. PMID:20306264
Chemotherapy: managing side effects and safe handling. PMID:19721789
In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. PMID:18246349
Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega. PMID:18196745
Tags:
Tags
More detailed information about this field from each metasource.
cancer
metasource: Fairsharing.org
version: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
disease
metasource: Fairsharing.org
version: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
Tags
More detailed information about this field from each metasource.
cancer
metasource: Fairsharing.orgversion: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
disease
metasource: Fairsharing.orgversion: FAIRsharing.org: CTCAE; Common Terminology Criteria for Adverse Events; DOI: https://doi.org/10.25504/FAIRsharing.dcsw6j; Last edited: Aug. 13, 2019, 4:26 p.m.; Last accessed: Jan 03 2022 7:12 p.m.
Need help integrating and/or managing biomedical data?